Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone646-975-2500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.62 million
Profitability
Miscellaneous
Employees79
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions
What is Progenics Pharmaceuticals' stock symbol?
Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."
How were Progenics Pharmaceuticals' earnings last quarter?
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) issued its earnings results on Thursday, March, 14th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.14. The biotechnology company had revenue of $3.24 million for the quarter, compared to analysts' expectations of $10.99 million. Progenics Pharmaceuticals had a negative net margin of 433.09% and a negative return on equity of 59.85%. View Progenics Pharmaceuticals' Earnings History.
When is Progenics Pharmaceuticals' next earnings date?
What price target have analysts set for PGNX?
4 brokerages have issued 12 month target prices for Progenics Pharmaceuticals' stock. Their predictions range from $6.50 to $15.00. On average, they expect Progenics Pharmaceuticals' share price to reach $11.6250 in the next year. This suggests a possible upside of 137.2% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.
What is the consensus analysts' recommendation for Progenics Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.
Has Progenics Pharmaceuticals been receiving favorable news coverage?
Headlines about PGNX stock have trended somewhat positive this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Progenics Pharmaceuticals earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
Who are some of Progenics Pharmaceuticals' key competitors?
Some companies that are related to Progenics Pharmaceuticals include Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), Zogenix (ZGNX), Mallinckrodt (MNK), Opko Health (OPK), Prestige Consumer Healthcare (PBH), Tricida (TCDA), Corcept Therapeutics (CORT), Innoviva (INVA), Cambrex (CBM), Inflarx (IFRX), Phibro Animal Health (PAHC), Theravance Biopharma (TBPH), Myovant Sciences (MYOV) and Aimmune Therapeutics (AIMT).
What other stocks do shareholders of Progenics Pharmaceuticals own?
Who are Progenics Pharmaceuticals' key executives?
Progenics Pharmaceuticals' management team includes the folowing people:
- Mr. Mark R. Baker, CEO & Director (Age 64)
- Mr. Patrick Fabbio, Exec. VP & CFO (Age 51)
- Dr. Vivien Wong, Exec. VP of Devel. (Age 62)
- Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46)
- Mr. Benedict Osorio, Chief Operating Officer (Age 62)
Who are Progenics Pharmaceuticals' major shareholders?
Progenics Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BKS Advisors LLC (0.14%), Boston Advisors LLC (0.03%), BNP Paribas Arbitrage SA (0.02%) and Virtu Financial LLC (0.02%). View Institutional Ownership Trends for Progenics Pharmaceuticals.
Which major investors are buying Progenics Pharmaceuticals stock?
How do I buy shares of Progenics Pharmaceuticals?
Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Progenics Pharmaceuticals' stock price today?
One share of PGNX stock can currently be purchased for approximately $4.90.
How big of a company is Progenics Pharmaceuticals?
Progenics Pharmaceuticals has a market capitalization of $414.26 million and generates $15.62 million in revenue each year. The biotechnology company earns $-67,660,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe.
What is Progenics Pharmaceuticals' official website?
How can I contact Progenics Pharmaceuticals?
Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]
MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
